Olynth E nasal spray

Olynth is a long-standing pharmaceutical brand specializing in nasal decongestants. Originally developed in Germany, the brand became a staple in the European market for treating symptoms of the common cold, sinusitis, and allergies. The active ingredient, xylometazoline, is known for its rapid and long-lasting effect, which has made Olynth a household name across several decades.

For many years, the brand was owned and managed by Johnson & Johnson through its consumer healthcare division. However, as part of a significant corporate restructuring in 2023, Johnson & Johnson spun off its consumer health segment into an independent, publicly traded entity named Kenvue.

In late 2025, a major consolidation in the consumer goods industry occurred when Kimberly-Clark, the global leader behind brands like Kleenex and Huggies, announced a definitive agreement to acquire Kenvue. This acquisition, which is projected to finalize during the second half of 2026, positions Kimberly-Clark as the ultimate parent company of Olynth, integrating the pharmaceutical brand into its extensive portfolio of essential hygiene and health products.